ReproCELL Incorporated
Research ReproCELL Incorporated (4978.T) on Bullrun: market cap JPY 12.05B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4978.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 12.05B
- Financial periodFY2026
- RevenueJPY 2.23B
- Revenue growth-25.0%
- Net income-JPY 591.69M
- Free cash flow-JPY 481.75M
- Gross margin45.5%
Valuation Snapshot
latest market cap is JPY 12.05B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 2.23B | -JPY 591.69M | -JPY 481.75M | 45.5% | -6.25 | JPY 2.94B | n/a | JPY 8.31B |
| FY2025 | JPY 2.98B | JPY 103.25M | -JPY 89.86M | 55.4% | 1.11 | JPY 2.82B | n/a | JPY 8.98B |
| FY2024 | JPY 2.43B | -JPY 31.42M | -JPY 203.88M | 46.2% | -0.37 | JPY 2.94B | n/a | JPY 8.31B |
| FY2023 | JPY 2.95B | -JPY 305.31M | -JPY 301.57M | 38.6% | -3.62 | JPY 1.91B | n/a | JPY 7.58B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 12.05B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About ReproCELL Incorporated
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ReproCELL Incorporated's market cap?
ReproCELL Incorporated's market capitalization is JPY 12.05B.
What does ReproCELL Incorporated do?
ReproCELL Incorporated provides stem cell research and drug discovery services in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, pluripotent stem cells, StemEdit gene edited iPSCs, mesenchymal stem cells (MSCs), and new immortalized cell lines and related reagents; and iPSC-derived exosomes.